drugset / Trial / NCT04916548

Repeated Neurocognitive Measurements in Depressed Patients

NCT04916548

Phase 1/2 Completed 15 enrolled Rebecca Price
NaSingle-groupOpen-labelBasic science

Summary

In this project, we will A) track the functioning of a collection of potential neurobiological targets for depression over time, B) examine how fluctuations in the functioning of those targets relates to real-world functioning, and C) in a subset of the sample, determine how the functioning in those targets is altered by a single dose of ketamine.

Timeline

Start
2021-09-16
Primary completion
2023-07-15
Completion
2023-08-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Ketamine Small molecule 0.5 mg/kg Intravenous

Indications